MedTrace Logo

Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab

NCT01706120 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2023-03-24

No results posted yet for this study

Summary

The addition of bevacizumab to first-line chemotherapy has been shown to improve progression free survival for patients with ovarian cancer. The purpose of this study is to explore the potential role of clinical and biologic factors in identifying those patients who benefit most from this combined therapy in terms of progression free and overall survival.

Conditions

Interventions

DRUG

Bevacizumab

• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 22 cycles

DRUG

Paclitaxel

• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 6 cycles

DRUG

Carboplatin

• Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles

Sponsors & Collaborators

  • Mario Negri Institute for Pharmacological Research

    collaborator OTHER

  • National Cancer Institute, Naples

    lead OTHER

Principal Investigators

  • Sandro Pignata, M.D., Ph.D. · National Cancer Institute, Naples

  • Nicoletta Colombo, M.D. · European Institute of Oncology

  • Francesco Perrone, M.D., Ph.D. · National Cancer Institute, Naples

  • Gennaro Daniele, M.D., Ph.D. · National Cancer Institute, Naples

  • Roldano Fossati, M.D. · Mario Negri Institute

  • Ciro Gallo, M.D. · University of Campania Luigi Vanvitelli

  • Irene Floriani, Ph.D. · Mario Negri Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01706120 on ClinicalTrials.gov